5395232022-04-012022-06-305395232022-04-012022-06-30in-bse-fin:OtherExpenses1Member5395232022-04-012022-06-30

ItemsThatWillNotBeReclassifiedToProfitAndLoss1

iso4217:INRiso4217:INRxbrli:shares

539523

ALKEM

NOTLISTED

INE540L01014

ALKEM LABORATORIES LIMITED

Equity

2022-04-01

2023-03-31

2022-08-05

2022-07-25

INR

Millions

First quarter

Single segment

The Company is exclusively engaged in pharmaceutical business

2022-08-05

11:00:00

2022-08-05

13:20:00

Not applicable

2022-04-01

2022-06-30

Unaudited

Standalone

20583500000

553100000

21136600000

6073100000

1839100000

1267700000

3870300000

220200000

568100000

5700200000

19538700000

1597900000

275100000

-78200000

196900000

1401000000

-4100000

1396900000

239100000

11.717

1. The above unaudited standalone financial results of the Company were reviewed and recommended by the Audit Committee on 4 August 2022 and subsequently approved by the Board of Directors at its meeting held on 5 August 2022. The auditors have issued an unmodified report on the financial results for the quarter ended 30 June 2022. The figures for the quarter ended 31 March 2022 are balancing figures between audited figures in respect of the full financial year and the unaudited published year-to-date figures up to the third quarter ended 31 December 2021, which were subjected to limited review. <BR> <BR> 2. The Company operates in one reportable business segment i.e. "Pharmaceuticals", accordingly no separate disclosure of segment has been made.

Other expenses

5700200000

Remeasurements of defined benefit plans

-6300000

-2200000